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Abstract
Background Hemolytic uremic syndrome (HUS) is a multisystemic disease. In a nationwide study, we characterized the inci-
dence, clinical course, and prognosis of HUS caused by Shiga toxin (Stx)–producing Escherichia coli (STEC) strains with
emphasis on risk factors, disease severity, and long-term outcome.
Methods The data on pediatric HUS patients from 2000 to 2016 were collected from the medical records. STEC isolates from
fecal cultures of HUS and non-HUS patients were collected from the same time period and characterized by whole genome
sequencing analysis.
Results Fifty-eight out of 262 culture-positive cases developed verified (n = 58, 22%) STEC-HUS. Another 29 cases had
probable STEC-HUS, the annual incidence of STEC-HUS being 0.5 per 100,000 children. Eleven different serogroups were
detected, O157 being the most common (n = 37, 66%). Age under 3 years (OR 2.4), stx2 (OR 9.7), and stx2a (OR 16.6) were
found to be risk factors for HUS. Fifty-five patients (63%) needed dialysis. Twenty-nine patients (33%) developed major
neurological symptoms. Complete renal recovery was observed in 57 patients after a median 4.0 years of follow-up. Age under
3 years, leukocyte count over 20 × 109/L, and need for dialysis were predictive factors for poor renal outcome.
Conclusions Age under 3 years, stx2, and stx2a were risk factors for HUS in STEC-positive children. However, serogroup or stx
types did not predict the renal outcome or major CNS symptoms.
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Introduction
Hemolytic uremic syndrome (HUS) is a complex,
multisystemic disease characterized by microangiopathic he-
molytic anemia, thrombocytopenia, and impaired kidney
function, and it is one of the most common causes of acute
kidney injury in children. It is most often caused, especially
among children, by Shiga toxin (Stx)–producing Escherichia
coli (STEC). The serotype O157:H7 has been previously rec-
ognized as the predominant cause of HUS worldwide [1].
However, this may arise from the diagnostic bias for this se-
rotype. Other serogroups such as O26, O55, O80, O103,
O104, O111, and O145 have been increasingly discovered
to cause STEC-HUS as well [2–6]. Shiga toxins (Stxs),
encoded by stx genes, are the major virulence factors to cause
thrombotic microangiopathy, which forms the histopatholog-
ical basis of HUS. Stxs can be divided into two major types
(Stx1 and Stx2) and several subtypes, with Stx2 usually lead-
ing to more severe symptoms [7, 8]. Stx subtypes have also
been found to differ in toxin potency [8–10]. HUS can some-
times be caused by other infectious agents such as
Streptococcus pneumoniae and genetic disorders regulating
the alternative pathway of the complement system (atypical
HUS) [11–13].
STEC is usually contracted through contaminated food or
drink, such as undercooked meat and unpasteurized milk or
vegetables, or transmitted from person to person. Cases appear
both sporadically and in epidemics. The development of HUS
among people infected with STEC has varied from 5 to 15%
in different studies and has been even higher in some studies
[14–17].
The treatment of STEC-HUS is symptomatic with no cu-
rative treatment. The use of antibiotics in the treatment has
long been considered contraindicated as there has been some
evidence that antibiotic use increases the likelihood of devel-
oping or worsening HUS [18, 19].
The prognosis of children with HUS has improved over
time, mostly due to advances in intensive care and dialysis.
Nevertheless, HUS in children is still associated with sig-
nificant morbidity and mortality. In the acute phase, approx-
imately half of the patients need kidney replacement thera-
py, and in about 25% of the cases, the disease is associated
with neurological symptoms [13, 20]. Mortality varies be-
tween 1 and 5% [13, 15, 20–22]. Patients need long-term
follow-up since approximately 20–25% develop some de-
gree of chronic kidney disease (CKD) [21, 23]. In addition,
5% develop severe sequelae such as kidney failure or neu-
rological damage [13, 21]. The length of oligo-anuria or
dialysis are found to be the most significant risk factors of
poor kidney prognosis, with the occurrence of neurological
symptoms, proteinuria, hypertension, dehydration, high
leukocyte, or hematocrit levels appearing to have some
prognostic value as well [21, 23, 24].
The purpose of this study was to estimate the annual inci-
dence of HUS among children < 17 years of age in Finland
and to characterize clinical features, treatment, and prognosis
of patients with STEC-HUS in a nationwide study. We also
aimed to investigate whether microbiological factors affect the
risk of developing HUS and the severity of the disease and
long-term outcome.
Methods
Collection of patient data
Patient data collection was performed retrospectively using
the hospital records and the National Infectious Diseases
Register. In 2000–2016, the five University Hospitals reported
STEC findings from a total of 262 pediatric patients (<
17 years of age) to the National Infectious Diseases Register,
as required by the Finnish legislation. STEC isolates from
fecal samples of pediatric patients were sent to the Finnish
Institute for Health and Welfare (THL) for further analysis.
Isolates from all pediatric patients (n = 262) with or without
HUS were included in this study. The fecal samples were
collected because of clinical suspicion of HUS and differential
diagnostics of diarrhea or due to screening of STEC in HUS
patient contacts.
In addition to the STEC-positive patients gathered from the
National Infectious Diseases Register, we retrospectively
identified all pediatric patients diagnosed and treated for
HUS in the five University Hospitals using the corresponding
ICD-10 diagnosis code D59.3. In addition, all patients with
the diagnosis code N17.9 for unspecified acute kidney injury
were reviewed, and cases that filled the diagnostic criteria for
HUS were included.
The clinical criteria for HUS were hemolytic anemia with a
hemoglobin (Hb) level < 10 g/dL, thrombocytopenia with a
platelet count < 150 × 109/L, and acutely reduced kidney func-
tion with a plasma creatinine concentration above the upper
normal limit for age. None of the patients included in the study
showed clinical or laboratory signs of other possible disorders
(SLE, glomerulonephritis) in the follow-up by pediatric ne-
phrologists. A verified STEC-HUS case was defined as a pa-
tient with clinical HUS and a culture-positive stool sample. A
probable STEC-HUS case was defined as a patient with clin-
ical HUS and the evidence of stx gene (by polymerase chain
reaction) or Stx toxins (by immunological methods) in an
enriched stool culture. In addition, culture- or Stx toxin–
negative patients with a history of diarrhea prior to the devel-
opment of HUS and HUS cases with at least one family mem-
ber positive for STEC in the stools were regarded as probable
cases.
For the calculation of the overall incidence of HUS in the
Finnish pediatric population, we also collected data on HUS
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cases caused by other infectious agents, such as Streptococcus
pneumoniae, or cases with atypical HUS. These 13 patients
were not included in the further analysis. The size of pediatric
population during the study period was obtained from
Statistics Finland (https://www.stat.fi).
The clinical and laboratory data of patients were collected
from the medical records until the most recent follow-up visit.
The data included patient’s gender and age at the time of
hospitalization, symptoms, clinical findings, treatment, e.g.
need, type, and length of dialysis or plasmapheresis, use of
antimicrobial or other medication, and also the possible ad-
ministration of red blood cells or platelets. The usual treatment
policy was to preserve the Hb above 6.0–7.0 g/dL. Platelet
transfusions were performed only in the case of bleeding or
prophylactically before surgical procedures, such as place-
ment of dialysis catheters. Laboratory data on Hb, leukocyte
count, platelet, blood urea nitrogen, creatinine, lactate dehy-
drogenase, cystatin C, transaminase, and amylase levels were
collected. For assessing the long-term outcome, glomerular
filtration rate (GFR) was evaluated using either 51Cr-EDTA
measurement or estimated (eGFR) from the CKiD Schwartz
formula [25]. Kidney function was considered decreased at
the last follow-up if GFR was under 90 mL/min/1.73m2
[26]. The limit for proteinuria was protein-to-creatinine
ratio > 20 g/mol or daily urine protein excretion (dU-Prot) >
200 mg. Hypertension was defined as systolic or diastolic
pressure ≥ 95th percentile for sex, age, and height [27].
Long-term outcome was reported only for patients with a
follow-up of at least 1 year. The national multicenter approach
of this study allowed reliable collection of follow-up data of
the patients. Long-term renal outcome was classified as poor if
the patient had decreased GFR, proteinuria, hypertension, or
medication for the latter two.
Microbiological characterization by whole genome
sequencing
Whole genome sequencing (WGS) for available isolates (N =
262) was performed by using MiSeq or HiSeq sequencers
(Illumina) as part of different projects at THL (N = 58), at
Institute National de Saude Doutor Ricardo Jorge (INSA),
Lisbon, Portugal (N = 44), and at SciLifeLab, Stockholm,
Sweden (N = 160). Bacterial DNA extraction and genomic
library preparation using Nextera chemistry (Illumina) were
performed by using methods and procedures in each labora-
tory as previously described [28, 29].
The WGS data analysis was performed at Karolinska
Institutet, Sweden. The sequencing reads were quality-
control processed and quality evaluated with QCtool pipeline
(https://github.com/mtruglio/QCtool). The processed reads
were assembled de novo with SPAdes (version: 3.12.0) in
“careful mode” [30]. The assemblies were annotated with
Prokka (version 1.11) [31].
Determination of serotypes, stx types, and subtypes
and eae
The assemblies were compared with VirulenceFinder data-
base (DTU, Denmark) (https://bitbucket.org/account/user/
genomicepidemiology/projects/DB) using BLAST+ v2.2.30
[32] to determine stx genotypes and the presence of intimin-
encoding gene eae. The cut-off values for gene identity and
alignment coverage were set to 90% in the VirulenceFinder
database search. Serotype was determined by comparing as-
sembly sequences to the SerotypeFinder database using
BLAST+ v2.2.30. In six cases, the samples were not available
at the time of study, and information concerning serotype, stx,
and eae was missed.
Statistical analysis
Statistical analyses were performed with SPSS (version 25) for
Windows (IBMCorp, Armonk, NY). Normally distributed var-
iables are reported as means and standard deviations (SD) and
comparison between the groups analyzed with Student’s t test.
Variables that did not show normal distribution are reported as
medians and their interquartile ranges (IQR) and analyzed with
Mann-Whitney U test. The chi-square test was used to compare
distributions of categorical variables between groups. Risk fac-
tors for HUS, major central nervous system (CNS) symptoms,
and renal outcome were assessed using a binary logistic regres-
sion model (for HUS, also adjusting for age and sex) and for
long-term renal outcome, also using multivariate analysis. In
these analyses, age groups were < 3 years and ≥ 3 years. The
results of logistic regression analyses are reported as odds ratios
with 95% confidence intervals and two-tailed p values.
Statistical significance was defined as p < 0.05.
Ethics
The Ethics Committee of the University of Helsinki approved
the use of patients’ information and the study protocol.
Results
Incidence of STEC infection and HUS
Fifty-eight out of the 262 (22%) children with STEC isolated
from the stool had verified STEC-HUS (Table 1). Of these, 56
isolates were available for serotyping and determination of stx
genotype by WGS. Twenty-nine cases had probable STEC-
HUS, including those with both culture- and toxin-negative
diarrhea and clinical HUS (20/29), toxin-positive but culture-
negative clinical HUS (3/29), and clinical HUS cases with a
STEC positive family member (6/29). Thus, altogether 87
cases with either verified (58, 67%) or probable (29, 33%)
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STEC-HUS were recognized, the total number of patients
being 291 (Table 1). No recurrent cases of HUS were seen.
Verified and probable STEC-HUS cases did not differ by age,
gender, duration of symptoms before hospitalization, or fre-
quency of diarrhea or bloody diarrhea.
Among Finnish children, the average annual incidence of
confirmed and probable STEC-HUS cases was 0.50 per
100,000 and that of all verified STEC cases was 1.5 per
100,000. During the same study period, 13 children had
HUS caused by non-E. coli etiology. Seven of these were
associated with infections caused by Streptococcus
pneumoniae (n = 5), Streptococcus pneumoniae, and
Influenza A (n = 1) or Campylobacter (n = 1). Two cases
had urinary tract infection caused by E. coli. Four patients
had atypical HUS including complement factor H mutation
(n = 2), complement factor I mutation (n = 1), and membrane
cofactor protein mutation (n = 1). Thus, the overall annual
incidence of HUS was 0.57 per 100,000 children.
Fifty-five of 87 (63%) cases with confirmed or probable
STEC-HUS were female, the risk of developing HUS being
higher among females than males (OR 2.01, CI 1.20–3.37,
p < 0.01). The median age of patients with HUS was 3.3 years
(1.4–7.5). The incidence was highest in the age group of 0-
and 1-year-old children (Fig. 1), < 3 years of age being a risk
factor for STEC-HUS (OR 2.36, CI 1.40–3.99, p < 0.005).
Microbiological characteristics
O157 was the most frequent (37/56, 66%) serogroup in cases
with STEC-HUS, followed by O26 serogroup (6/56, 11%).
Altogether 11 different serogroups were found to cause
STEC-HUS (Fig. 2). Two isolates were positive for stx1 only
(1 stx1a and 1 stx1c), 51 for stx2 only (49 stx2a, 1 stx2b, and 1
stx2c), and 3 for both stx1 and sxt2 (all stx1a and stx2a). Cases
with O157 and non-O157 STEC-HUS did not differ with
regard to presence of stx1 or stx2. Most of the cases (88%)
had eae-positive STEC. Among patients with STEC infection,
the eae gene was significantly associated with the serogroup
O157 when compared with non-O157 cases (98% vs. 75%,
p < 0.001).
Among the STEC-positive cases, serogroup O157 was
slightly more likely to cause HUS as compared with non-
O157 serogroups but without significant difference (OR
1.83, p = 0.055) (Table 2). After adjustment for sex and age,
the difference was, however, significant. Stx2, and especially
stx2a subtype were found to be risk factors for HUS (p <
0.001) (Table 2), while stx1 alone or together with stx2 seemed
to lower the risk of developing HUS (Table 2). Although eae
was found in 93% of cases with HUS, the risk of developing
HUS was not found to be significantly increased among pa-
tients with eae (Table 2).
Clinical features of STEC-HUS cases
The median duration of symptoms before the patient was ad-
mitted to hospital was 5 (3–7) days. Diarrhea preceded HUS
in 80 (92%) cases, being bloody in 49 (61%). Vomiting was
the second most common symptom (67%), followed by fever
(37%) and abdominal pain (29%). Hb declined to the median
nadir value of 6.0 (5.6–6.6) g/dL and platelets to 31 (22–44) ×
109/L. The median creatinine level at the time of hospitaliza-
tion was 106 (50–303) μmol/L and peak value 343 (117–480)
μmol/L. Forty-four (51%) patients progressed to anuria.
Twenty-nine patients (33%) developedmajor CNS symptoms.
The renal, CNS, and extrarenal findings are presented in more
detail in Table 3.
Treatment
Fifty-five patients (55/87, 63%) needed dialysis for a median
of 10 (6–16) days. Twenty-five of the 55 patients (45%) re-
quired dialysis for more than 10 days. Treatment modalities
were hemodialysis (HD) in 47 cases, peritoneal dialysis (PD)
in six cases, and both HD and PD in two. The number of
dialysis sessions varied from one to 41. Two patients became
dependent on dialysis and were subsequently transplanted
(8 months and 1.5 years after the development of HUS, re-
spectively). Plasma exchanges (PE) were performed on seven
patients (before the year 2012). Red blood cell transfusions
were given to 74 out of 87 (85%) patients (median three trans-
fusions per patient) to maintain an adequate Hb level. Platelet
transfusions were given to 47 out of 87 (54%) (median one
transfusion per patient). Forty-seven (54%) patients received
antimicrobial treatment. In two cases (4%), the treatment was
started prior to the hospitalization, in 9 (19%) before starting
dialysis, and in 37 cases (79%) later during the hospitalization.
Table 1 The study population and data sources
Non-HUS STEC cases, all 204
STEC-HUS cases, all 87
Verified STEC-HUS cases1 58
Probable STEC-HUS cases, all 29
Culture negative, PCR positive2 3
Bloody diarrhea, culture and PCR negative2 20
Clinical HUS, family member+2 6
Total 291
Non-STEC HUS, all2 13
Streptococcus pneumonia 5
Streptococcus pneumoniae and Influenza A 1
Campylobacter 1
Complement defect 4
Escherichia coli urinary tract infection 2
1 From the National Infectious Diseases Register
2 From patient records
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Two patients received eculizumab due to severe neurological
symptoms. Median treatment time in the hospital during the
acute phase was 17 (12–24) days.
Outcome
Long-term follow-up data (> 12 months) was available on 77
HUS cases. The median follow-up time was 4.0 (2.0–6.4)
years. The overall outcome of children with HUS was good,
with no mortality. Eight patients (10%) had mildly decreased
kidney function (GFR 60–90 mL/min/1.73 m2) and two
(2.6%) had more severely affected GFR (31 and 45 mL/min/
1.73 m2) at the end of follow-up. In addition, two (2.6%)
patients had progressed to CKD stage 5 and received a kidney
transplantation. Altogether 10 (13%) patients had proteinuria,
eight (10%) had persistent hypertension, and nine (12%) had
medication for either hypertension and/or for proteinuria (an-
giotensin-converting enzyme-inhibitor or angiotensin II re-
ceptor blocker in eight and beta-blocker in one) at the end of
follow-up. Two cases (2.6%) suffered from neurological long-
term complications.
Risk factors of renal and neurological sequelae
Peak leukocyte count over 20 × 109/L and anuria and Hb level
over 9.5 g/dL at the time of admission were predictive of
dialysis treatment (OR 3.19, p < 0.05, OR 121.18, p < 0.001,
and OR 2.75, p < 0.05, respectively) (Table 4). The plasma
creatinine (246 vs. 69 μmol/L, p < 0.001) and lactate dehy-
drogenase (2500 vs. 1465 U/L, p < 0.005) levels at the time of
admission and the peak urea value (35.1 vs. 18.2 mmol/L, p <
0.001) were also more likely to be higher among patients
needing dialysis. These children had also more often received
antimicrobials than patients without dialysis (40/54, 74% vs.
7/32, 22%, p < 0.001). If only those patients in whom antimi-
crobial treatment was started before dialysis were taken into
account, the use of antibiotics did not seem to increase the risk
of dialysis (Table 4).
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Patients needing dialysis more often had major neurologi-
cal symptoms than those treated without dialysis (25/55, 45%
vs. 4/32, 13%, p < 0.005). Patients with major CNS symptoms
had also higher creatinine, peak urea, and leukocyte counts
than those with either mild or no neurological signs (median
peak creatinine 426 vs. 253 μmol/L, p < 0.05, median peak
urea 34.4 vs. 26.1 mmol/L, p < 0.05 and median peak leuko-
cyte count 22.2. vs. 15.5 × 109/L, p < 0.005). Peak leukocyte
count over 20 × 109/L and anuria predicted major CNS symp-
toms (Table 4).
Risk factors of poor long-term renal outcome were age
under 3 years (OR 5.91), dialysis treatment in general (OR
7.03) and dialysis > 10 days (OR 4.14), and leukocyte count
over 20 × 109/L (OR 4.36) (Table 5). In addition, the length of
anuria was associated with a worse outcome, the median time
of anuria being 9 (0–16) days in patients with renal sequelae at
the end of follow-up compared with 0 (0–8) days in patients
with good long-term renal outcome. In a multivariate analysis,
only age under 3 years and dialysis remained independent risk
factors (OR 8.4 and 10.6, p < 0.01).
Serogroups and stx types as a risk factor could be analyzed
in 56 HUS patients with WGS information available.
Serogroup O157 or stx types or were not linked with the need
for dialysis (Table 4). Serogroup and stx types were not found
to be risk factors for major CNS symptoms or for poor long-
term renal outcome either (Tables 4 and 5). No difference in
the outcome (or dialysis, CNS symptoms, or poor long-term
renal outcome) was found based on whether STEC was iso-
lated from the stool or not.
Discussion
In this nationwide survey, we analyzed the epidemiological,
bacteriological, and clinical data of 87 pediatric patients who
suffered from HUS caused by STEC during a 17-year period
in Finland. The majority (34/56, 61%) of the HUS cases were
caused by STEC serogroup O157 and Shiga toxin subtype
Table 2 Serogroups and toxins as risk factors for HUS in 256 STEC positive patients using binary logistic regression model
HUS (56) STEC without HUS (200) OR (95% CI) p value Adjusted OR* p value
Serogroup O157 37 (66%) 103 (52%) 1.83 (0.99–3.41) NS 2.14 (1.11–4.12) 0.02
Serogroup O26 6 (11%) 20 (10%) 1.08 (0.41–2.83) NS 1.12. (0.41–3.19) NS
Serogroup O121 4 (7%) 4 (2%) 3.77 (0.91–15.58) NS 2.66 (0.61–11.60) NS
Stx1(with or without Stx2) 5 (9%) 118 (59%) 0.07(0.03–0.19) < 0.001 0.07 (0.03–0.18) < 0.001
Stx1 alone 2 (4%) 54 (27%) 0.10 (0.02–0.43) 0.002 0.09 (0.02–0.39 0.001
Stx1a 4 (7%) 108 (54%) 0.07 (0.03–0.19) < 0.001 0.07 (0.02–0.19) < 0.001
Stx2 (with or without Stx1) 54 (96%) 147 (74%) 9.74 (2.29–41.33) 0.002 11.03 (2.56–47.53) 0.001
Stx2 alone 51 (91%) 82 (41%) 14.68 (5.62–38.36) < 0.001 14.84 (5.62–39.20) < 0.001
Stx2a 51 (91%) 76 (38%) 16.64 (6.36–43.54) < 0.001 17.41 (6.55–46.27) < 0.001
Stx2c 1 (2%) 56 (28%) 0.05 (0.01–0.35) 0.003 0.47 (0.06–4.00) NS
Stx1 and Stx2 3 (5%) 65 (33%) 0.12 (0.04–0.39) < 0.001 0.12 (0.04–0.42) 0.001
eae 52 (93%) 172 (86%) 2.12 (0.71–6.31) NS 1.92 (0.63–5.81) NS
CI confidence interval, NS nonspecific, OR odds ratio, aOR adjusted odds ratio with confidence intervals for age groups < 3 and ≥ 3 years and sex
Table 3 Clinical consequences of 87 patients with STEC-HUS
Variables n (%)
Anuria 44 (51)
Oliguria 25 (29)
Major CNS symptoms 29 (33)
Seizures 24 (28)
Impaired consciousness 15 (17)
Hemiparesis 4 (5)
Minor CNS symptoms 12 (14)
Lethargy 8 (9)
Irritability 2 (2)
Vision abnormality 1 (1)
Speech abnormality 1 (1)
Fluctuating hemiparesis 1 (1)
Hypertension 30 (34)
Extrarenal manifestations
Elevated transaminase level 43 (49)
Pleural effusion 17 (20)
Elevated amylase level 13 (15)
Pericardial effusion 6 (7)
Ascites 5 (6)
Decreased myocardial function 4 (5)
Pulmonary embolism 1 (1)
Rhabdomyolysis 1 (1)
Gallstones* 1 (1)
*Developed 1 month after the acute episode
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stx2a. As expected, kidneys and CNS were the main target
organs and nearly two thirds of the patients needed dialysis for
a median of 10 days. Neurological findings were present on
admission or developed during hospitalization in one third of
our patients. Although the overall outcome of the patients was
good, two patients (2.3%) needed kidney transplantation later.
In this study, the incidence of STEC infection (1.5/
100,000) was consistent with many earlier reports, although
somewhat lower than recently reported in Sweden [33–35].
During the study period, a total of 262 STEC cases were
reported in Finland. Of these, 22% progressed to HUS, which
is somewhat higher than reported earlier, but equals the fre-
quency in the recent German outbreak [1, 3, 10, 17, 36].
However, the true number of STEC infections is most proba-
bly higher as it is likely that stool cultures were not taken from
all positive patients and the detection rates are not complete.
The average annual incidence rate of HUS in Finland (0.57
cases per 100,000 children) equals the incidence rates in
Germany, Austria, British Isles, France, and Norway [14, 15,
20, 33]. Consistent with most of the previous studies [10, 14,
20, 37], the majority (66%) of HUS cases in Finland were
caused by STEC serogroup O157. The proportion of non-
O157 serogroups (O26, O80, O103, O104, O145), however,
has increased since the early 2010s [10, 33]. A similar change
has also been reported from Switzerland and Australia, where
O157:H7 serotype is nowadays a minor cause of HUS [13,
38]. Other serotypes, such as O26:H11/H-, have been associ-
ated with HUS patients with a potentially severe clinical
picture [6]. In our survey, 11% of the cases with STEC-HUS
were caused by O26 serogroup strains.
There is controversy as to whether the STEC serotype is a
risk factor for developing HUS [8, 10, 17, 35]. In our study,
the risk of developing HUS did not differ among patients with
serogroup O157 when compared with non-O157 STEC cases
or when patients with serogroup O26 were compared with
others, but after adjustment for age and sex, serogroup O157
was found to increase the risk of HUS. An association be-
tween the development of HUS and the presence of stx2 gene,
especially subtype stx2a (with or without stx2c) and stx2d, has
been described [6, 8, 10, 39, 40]. We found stx2a to be a risk
factor, whereas stx1, stx1a, and stx2c were associated with a
reduced risk of developing HUS. Patients having both stx1
and stx2 had lower risk of developing HUS than patients with
only stx2, consistent with earlier literature [1]. Several other
virulence factors contribute to the pathogenicity of STEC, and
one of them is eae, which encodes intimin [8]. In our material,
however, eae was not found to significantly increase the risk
of developing HUS.
Among the STEC-positive children, age < 3 years was a
risk for HUS, which is consistent with the recent findings in
Norway [14]. Previously, age less than 5 years has been re-
ported to be a risk for development of HUS [8, 10, 36]. In a
recent study, females were more likely to develop HUS [36],
as was also the case in our study. STEC-HUS was rare in
children over 10 years of age and other etiologies must there-
fore be kept in mind and ruled out in teenage HUS patients.
Table 4 Comparison of clinical and microbiological findings in patients on temporary dialysis (n = 55) with those not needing kidney replacement
therapy (n = 32) as well as in patients with (n = 29) and without (n = 58) major CNS symptoms using binary logistic regression model
Number Short-term kidney function Major CNS symptoms
Dialysis (55) No dialysis (32) OR (95% CI), p value CNS (29) No CNS (58) OR (95% CI), p value
Age < 3 years 25 (45%) 16 (52%) 0.83 (0.35–2.00), NS 16 (55%) 25 (43%) 1.63 (0.66–3.99), NS
Antimicrobial treatment, all 40 (74%)a 7 (22%) 10.20 (3.62–28.75), < 0.001 22 (76%) 25 (44%)a 10.20 (3.62–28.75), < 0.001
Antimicrobial treatment,
started before dialysisc
9 (17%)a 7 (22%) 0.71 (0.24–2.15), NS 3 (10%) 25 (44%)a 0.15 (0.04–0.54), 0.004
Leukocytes > 20 E9/L 30 (57%)b 9 (29%)a 3.19 (1.24–8.22), 0.02 18 (64)a 21 (38%)b 3.19 (1.24–8.22), 0.02
Hemoglobin > 9.5 g/dL 33 (62%) 12 (38%) 2.75 (1.11–6.80), 0.03 19 (66%) 26 (46%)b 2.19 (0.87–5.55), NS
Presence of anuria 43 (80%)a 1 (3%) 121.18 (14.86–988.16), < 0.001 20 (69%) 24 (42%)a 3.06 (1.19–7.88), 0.02
O157d 26 (74%) 11(52%) 2.62 (0.84–8.24), NS 15 (79%) 22 (59%) 2.56 (0.71–9.23), NS
Stx1 aloned 2 (6%) 0 (0%) 1 (5%) 1 (3%) 2.00 (0.12–33.86), NS
Stx2 aloned 31 (89%) 20 (95%) 0.39 (0.04–3.72), NS 17 (89%) 34 (92%) 0.75 (0.11–4.92), NS
Stx1 and Stx2d 2 (6%) 1 (5%) 1.21 (0.10–14.24), NS 1 (5%) 2 (5%) 0.97 (0.08–11.46), NS
OR odds ratio, CI confidence interval, NS nonspecific, CNS central nervous system
aData missing from one patient
b Data missing from two patients
c Data analyzed taking into account only those cases, in whom the antimicrobial treatment was started before dialysis in the dialysis group
d Includes 56 patients [(1) renal short-term outcome analysis: 35 with dialysis and 21without and (2) major CNS symptoms; 19with CNS symptoms and
37 without], on whom whole genome sequencing data were available
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The clinical picture of most HUS patients was typical: the
majority of the patients had bloody diarrhea but no fever. Half
of the patients developed anuria and 63% needed dialysis for a
median of 10 days, as seen in earlier studies [20, 33, 41]. Pleural
and/or pericardial effusion, ascites, transient elevation in liver
enzymes, and/or amylase and hypertension were quite common,
observed in almost half of the patients. About half of the patients
had received platelet transfusions, in most cases before inserting a
hemodialysis catheter. During the early years of this study, plate-
lets were given also before PD-catheter placement, which has
recently been shown to be unnecessary [42]. A third of the pa-
tients had major neurological symptoms, which is more than
reported in previous studies [14, 20]. We do not know the expla-
nation for this. Importantly, however, the outcome of the patients
was optimistic with no deaths and neurological sequelae in only
two patients. While neurological manifestations are the main
cause of acute mortality in HUS (2–5%) [13, 20, 22, 37, 41],
none of our patients died. Seven childrenwith severe neurological
symptoms were treated with PE, which was used as a treatment
modality in many centers, especially in cases with neurological
symptoms [11]. After cumulative evidence that PE brought no
short- or long-term benefits and could be even harmful [43, 44], it
was discontinued in Finland. In our study, however, patients treat-
ed with PE did not develop long-term neurological complica-
tions, nor did they need dialysis more frequently than others (data
not shown). Two of our patients received eculizumab due to
severe neurological symptoms. One child had a mild hemiparesis
and decreased kidney function (GFR< 60mL/min/1.73m2) at the
end of follow-up. The other child recovered fully.
About half of our patients received antimicrobials, usually
not directed against STEC or HUS per se. The main indica-
tions were suspicion of secondary infections (or prevention of
intravenous or urinary catheter or, for example, rising infec-
tion parameters and stomach pain causing fear of bowel per-
foration). The current general opinion is that antibiotics should
be avoided at least during the diarrheal phase since they may
increase local Shiga toxin concentrations due to the lysis of
toxin-containing bacteria [18, 36, 45]. Although a recent
meta-analysis [19] failed to show any associations between
antibiotic use and higher incidence of HUS, antibiotics are
still not recommended in STEC infections or during HUS.
In our study, the use of antimicrobial medication was more
common in patients who needed dialysis. However, it was
usually started after the initiation of dialysis. When only those
cases inwhom antibiotics were started before the dialysis were
taken into account, antibiotic use did not seem to predict the
need for dialysis treatment or increase the risk of development
of neurological symptoms. No association was seen between
antibiotic use and poor long-term outcome.
Children with STEC-HUS are at risk for long-term compli-
cations. Complete renal recovery (normal GFR, no protein-
uria, and no hypertension) was seen in 57 of 77 (74%) patients
after a median follow-up of 4.0 years. This is in line with an
earlier meta-analysis showing long-term renal sequelae (hy-
pertension, GFR < 80 mL/min/.173m2, and/or proteinuria) in
25% of the patients [23]. In two studies with longer follow-up
(9.6 and 8.8. years), the frequency of renal-related sequelae
was even higher, 39% and 47%, respectively [24, 46]. In our
Table 5 Comparison of patients with poor renal outcome (decreased GFR, proteinuria, and/or hypertension with or without medication) (n = 20) to
those with no renal impairment (n = 57) using binary logistic regression model
Number Renal outcome
Poor outcome (20) Good outcome (57) OR (95% CI) p value
Age < 3 years 16 (80%) 23 (40%) 5.91 (1.75–19.96) 0.004
Antimicrobial treatment 15 (75%) 28 (50%)a 3.00 (0.96–9.38) NS
Leukocytes > 20 × 109/L 15 (75%) 22 (41%)b 4.36 (1.38–13.76) 0.012
Platelet infusions 10 (50%) 31 (57%)b 0.74 (0.27–2.08) NS
Major CNS symptoms 10 (50%) 19 (33%) 2.00 (0.71–5.63) NS
Presence of anuria 14 (70%) 25 (45%)a 2.90 (0.97–8.62) NS
Need of dialysis 18 (90%) 32 (56%) 7.03 (1.49–33.19) 0.014
Dialysis time over 10 days 11 (55%) 13 (23%) 4.14 (1.4–12.14) 0.010
Serogroup O157c 8 (57%) 26 (70%) 0.56 (0.16–2.01) NS
Stx1 alonec 1 (7%) 1 (3%) 2.77 (0.16–47.56) NS
Stx2 alonec 12 (82%) 34 (96%) 0.53 (0.08–3.56) NS
Stx 1 and 2c 1 (7%) 2 (5%) 1.35 (0.11–16.13) NS
OR odds ratio, CI confidence interval, CNS central nervous system, NS nonspecific
a Data missing from one patient
b Data missing from three patients
c Includes only 51 patients (14 with poor and 37 with good long-term renal outcome)
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study, two (2.3%) patients progressed to CKD stage 5 and
received a kidney transplant, consistent with the earlier litera-
ture [13, 21]. Similarly, two children (2.3%) suffered from
long-term neurological complications.
Identification of risk factors for severe disease and poor
long-term outcome would help in managing STEC-HUS
children. Young age (< 3 years) and dialysis > 10 days were
clearly risk factors for later renal sequelae. This is in line
with the study of Oakes et al. [46], who found that anuria
over 10 days substantially increased the risk for low GFR
and proteinuria. Creatinine, leukocytes, Hb, lactate dehy-
drogenase, and urea were significantly higher among pa-
tients needing dialysis. Blood leukocyte count > 20 × 109/
L during the acute phase and Hb > 9.5 g/dL on admission
also predicted the need for later dialysis. Interestingly, leu-
kocytes > 20 × 109/L also predicted major CNS symptoms.
High leukocyte count and hemoconcentration have both
been found to be associated with higher risk of death [22].
Twenty-five (86%) of the 29 cases with major CNS symp-
toms needed dialysis. In 20 children, the CNS symptoms
started before dialysis (median 2 days after the hospitaliza-
tion), which speaks against an association between dialysis
and neurological manifestations.
According to our results, serotype, stx1/stx2 type, and pres-
ence of the eae gene could not predict which HUS patients
were at risk of developing more severe clinical outcome (e.g.
need of dialysis, CNS symptoms) or long-term renal sequelae.
In one earlier study, serotype O157:H7 was associated with a
longer need for dialysis treatment [20].
Our study has some limitations. STECwas not isolated from
all patients. Fecal STEC excretion in infected patients generally
only lasts a few days [33], and our patients were admitted to the
hospital after a median of 5 days of symptoms. STEC labora-
tory diagnostics have improved over time. During the early
years of the study period, mainly culture-confirmed STEC
cases were notified by clinical laboratories, whereas PCR-
positive but culture negative cases were not before year 2013.
This may underestimate the true number of STEC infections.
On the other hand, since 2007, guidelines to control STEC
infection have recommended screening of family members of
patients with STEC infections. The retrospective nature of the
study also means that in some cases, laboratory or clinical data
are missing. Due to the small Finnish population (total 5.5
million), the number of HUS cases remains low.
To conclude, HUS is a rare but severe disease typically
affecting young children. Over half of the patients need dial-
ysis, the risk being greatest in children under 3 years of age.
Besides young age, high leukocyte count is associated with
the severity of the disease. Stx2 and stx2a are linked to an
increased risk of developing HUS, but the stx types do not
predict the renal outcome or major CNS symptoms. Finally,
approximately one quarter of the patients develop long-term
renal or neurological sequelae.
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